Company intelligence / Profile preview

Tian Medical

Libertyville, Illinois, United Statestianmedical.com ↗

Ownership: Private
Employees: ~28
Development stage: Commercial

Overview

The company’s Tx360® Nasal Applicator delivers medication directly to the sphenopalatine ganglion via the nasal cavity. It received FDA 510(k) clearance in 2010 and has been evaluated in at least one completed Phase 3 clinical trial for chronic migraine. The device enables minimally invasive SPG blocks with positive outcomes reported by both clinicians and patients.

Therapeutic areas: Neurology
Modalities: Device (specifically a nasal applicator for targeted drug delivery)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Tx360 Nasal Applicator

Commercial

Indications: Migraine, Headache

Beyond the preview

Go deeper on Tian Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tian Medical.

Explore the full profile